1. FDA approves teclistamab-cqyv. for relapsed or refractory multiple myeloma [ https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma
2. FDA grants accelerated approval to. elranatamab-bcmm for multiple myeloma [ https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma
3. FDA grants accelerated approval to. talquetamab-tgvs for relapsed or refractory multiple myeloma [ https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-talquetamab-tgvs-relapsed-or-refractory-multiple-myeloma
4. Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood cancer J. 2020;10(9):94.
5. Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor–dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727–38.